NO995035L - 5,6,7-Trisubstituted-4-aminopyrido [2,3-D] pyrimidine Compounds - Google Patents

5,6,7-Trisubstituted-4-aminopyrido [2,3-D] pyrimidine Compounds

Info

Publication number
NO995035L
NO995035L NO995035A NO995035A NO995035L NO 995035 L NO995035 L NO 995035L NO 995035 A NO995035 A NO 995035A NO 995035 A NO995035 A NO 995035A NO 995035 L NO995035 L NO 995035L
Authority
NO
Norway
Prior art keywords
compound
aminopyrido
trisubstituted
pyrimidine compounds
mammal
Prior art date
Application number
NO995035A
Other languages
Norwegian (no)
Other versions
NO995035D0 (en
Inventor
Shripad S Bhagwat
Richard J Perner
Yu-Gui Gu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NO995035D0 publication Critical patent/NO995035D0/en
Publication of NO995035L publication Critical patent/NO995035L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Forbindelse som har formel (II) iVrR< ^ ifr^- L \r^- ta 5 (10 hvor R1, R2, R3, R4 og R5 er definert, en fremgangsmåte ved inhibering av adenosinkinase ved å administrere en for- bindelse derav, en farmasøytisk sammensetning omfattende en terapeutisk effektiv mengde av en forbindelse derav oven- for, i kombinasjon med en farmasøytisk akseptabel bærer, en fremgangsmåte ved behandling av cerebral iskemi, epilepsi, smerte, nocipersepsjon, inflammasjon og sepsis i et patte- dyr som trenger slik behandling, omfattende å administrere til pattedyret en terapeutisk effektiv mengde av en for- bindelse derav, og fremgangsmåter ved fremstilling derav.A compound having formula (II) iVrR <^ ifr ^ - L \ r ^ - ta 5 (10 wherein R1, R2, R3, R4 and R5 are defined, a method of inhibiting adenosine kinase by administering a compound thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound thereof above, in combination with a pharmaceutically acceptable carrier, a method of treating cerebral ischemia, epilepsy, pain, nociception, inflammation and sepsis in a mammal in need of such treatment , comprising administering to the mammal a therapeutically effective amount of a compound thereof, and methods of preparing it.

NO995035A 1997-04-16 1999-10-15 5,6,7-Trisubstituted-4-aminopyrido [2,3-D] pyrimidine Compounds NO995035L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84348497A 1997-04-16 1997-04-16
PCT/US1998/007201 WO1998046604A1 (en) 1997-04-16 1998-04-13 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds

Publications (2)

Publication Number Publication Date
NO995035D0 NO995035D0 (en) 1999-10-15
NO995035L true NO995035L (en) 1999-12-15

Family

ID=25290123

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995035A NO995035L (en) 1997-04-16 1999-10-15 5,6,7-Trisubstituted-4-aminopyrido [2,3-D] pyrimidine Compounds

Country Status (19)

Country Link
EP (1) EP0975633A1 (en)
JP (1) JP2001520654A (en)
KR (1) KR20010006462A (en)
CN (1) CN1252069A (en)
AR (1) AR012437A1 (en)
AU (1) AU741033B2 (en)
BG (1) BG103853A (en)
BR (1) BR9809056A (en)
CA (1) CA2286592A1 (en)
CO (1) CO4940470A1 (en)
HU (1) HUP0001443A3 (en)
IL (1) IL131617A0 (en)
NO (1) NO995035L (en)
NZ (1) NZ337125A (en)
PL (1) PL336265A1 (en)
SK (1) SK140099A3 (en)
TR (1) TR199902550T2 (en)
WO (1) WO1998046604A1 (en)
ZA (1) ZA983175B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057040A1 (en) * 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
KR100639772B1 (en) 2001-02-12 2006-10-30 에프. 호프만-라 로슈 아게 6-substituted pyrido-pyrimidines
CN107744520A (en) * 2017-10-25 2018-03-02 南京多宝生物科技有限公司 Pyrimidines are preparing the application in promoting small bowel peristalsis medicine
CN112209924B (en) * 2019-07-09 2022-04-05 中国科学院天津工业生物技术研究所 Selective adenosine A1Receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB774094A (en) * 1953-01-02 1957-05-08 Wellcome Found Improvements in or relating to pyrimidine compounds
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds

Also Published As

Publication number Publication date
HUP0001443A3 (en) 2001-01-29
PL336265A1 (en) 2000-06-19
KR20010006462A (en) 2001-01-26
CO4940470A1 (en) 2000-07-24
BR9809056A (en) 2000-08-01
NO995035D0 (en) 1999-10-15
CA2286592A1 (en) 1998-10-22
JP2001520654A (en) 2001-10-30
IL131617A0 (en) 2001-01-28
TR199902550T2 (en) 2000-04-21
CN1252069A (en) 2000-05-03
BG103853A (en) 2000-06-30
EP0975633A1 (en) 2000-02-02
AU7108098A (en) 1998-11-11
ZA983175B (en) 1998-10-21
AR012437A1 (en) 2000-10-18
NZ337125A (en) 2001-06-29
WO1998046604A1 (en) 1998-10-22
AU741033B2 (en) 2001-11-22
HUP0001443A2 (en) 2000-10-28
SK140099A3 (en) 2000-05-16

Similar Documents

Publication Publication Date Title
CA2150123A1 (en) Aminomethylene substituted non-aromatic heterocycles
CA2098076A1 (en) Imidate prodrugs of pharmaceutically useful anticonvulsant sulfamates
CA2293823A1 (en) 4&#34;-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
BG100635A (en) Substituted n-/indol-2-carbonyl/- - alanineamides and their derivatives as antidiabestic preparations
MY116915A (en) Substituted indazole analogs
WO1998022493A3 (en) N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
NO984470L (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
CA2107223A1 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
NO20001169L (en) 6.9-bridge erythromycin derivatives
CA2286511A1 (en) Novel macrolide derivatives
NO20002099L (en) 6,11-bridged erythromycin derivative
BG104340A (en) 3&#39;-n-modified 6-o-substituted erythromycin ketolide derivatives having antibacterial activity
NO995036L (en) 5,7-Disubstituted 4-Aminopyrido [2,3-d] Pyrimidine Compounds and Their Use as Adenosine Kinase Inhibitors
EP1142881A4 (en) Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
NO995035L (en) 5,6,7-Trisubstituted-4-aminopyrido [2,3-D] pyrimidine Compounds
DE69122858D1 (en) THERAPEUTIC BENZAZEPINE COMPOUNDS
KR100853955B1 (en) Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase ? and ? inhibitors
NO995033L (en) 6,7-disubstituted-4-aminopyrido [2,3-D] pyrimidine
WO1990012577A3 (en) Topical anti-angiogenic as hair growth inhibitors
AP9801235A0 (en) Erythromycin derivatives.
CA2208032A1 (en) Substituted amidinonaphthyl ester derivative
MX9604692A (en) Quinoxaline derivatives for treating tinnitus.
AU6919398A (en) Heterocyclic compounds and their preparation and use
MXPA98005355A (en) 5-[(heteroaryl) alkyl]-3 -oxo-pyrido [1, 2-a] benzimidazole -4-carboxamide derivatives useful in treating central nervous system disorders.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application